Recent News

August Rally Fading-Buyers On Hold in Light Summer Trading:Top Pick FBT

Large Caps Rule Macro and Seasonal Risks Create a Choppy Market The August biotech rally has taken us to the midpoint of the February top and May bottom and is faltering. Look at the XBI SPDR S&P biotech ETF (XBI), a proxy for momentum and smaller cap trading, up 8.7% over 30 days despite a […]

Continue Reading →

Buy Mid and Small Cap Biotech Stocks For A 4th Quarter Rally..Update 8/20

Update 8/20/14     IWM at $115, NASDAQ at 4528 Rayno Focus Stocks Achillion (ACHN) at 52 week high up 204% YTD and 48 % over 30 days. Gilead (GILD) new all time high at $101.36. Rayno Large Cap Biopharmaceuticals Portfolio (ALXN, AMGN, BIIB, FBT, GILD, REGN,RHHBY)  up 24.3% YTD. A coincident rally in IWM […]

Continue Reading →

Rayno Large Cap Biopharmaceutical Portfolio Up 17.5% YTD

Biotech ETFs or Large Caps Are Best Plays  In March 2014 we recommended an overweight in large cap biotech stocks due to volatility and higher risk of smaller cap stocks lacking revenue visibility. As we move into the fourth quarter we will reassess upside in the usually bullish end of year time frame. However many […]

Continue Reading →

Biopharmaceutical Stocks Take 2% Hit- Underperform Market in July

Biotech Stocks Take a 2+% Hit-Risk Off Again Bull Market Intact But Expect Choppy Summer Tape As of our previous portfolio review we are 15-20% cash and overweight large caps. The sell-off on July 31 hit all biotech stocks.However all major ETFs are up YTD with our recommended large cap weighted FBT up 17% YTD. […]

Continue Reading →

Green Day with Rayno Biopharmaceutical Stocks Up >2%

Some Huge Moves Today Brings Hope For Summer Rally ETFs Up: FBT $83 up 2.58%, IBB $254.78 up 1.14%, XBI $148.9 up 3.28%. Rayno Large Cap Portfolio: up 14,4% YTD with Biogen Idec(BIIB) and Gilead (GILD) leaders; near July highs. Virtually everything is up but big winners are: Ariad (ARIA $6.17) up 9.98%, Pharmacyclics (PCYC $124.75) […]

Continue Reading →

Rayno DX and Tools Mid Year Review and AACC Update: ABAX, ILMN, HOLX, TMO.. Update-2

Update -2 Aug. 1 Draft Guidance on LDTs Coming from FDA in 60 Days: Tests Must Be Validated More regulation coming means greater development costs and potential time delays for clinical tests in development and currently marketed as LDTs . Presumably LDT tests will be allowed to remain on the market. Potential intermediate term impact […]

Continue Reading →